MAP3K2 and pancreatic adenocarcinoma: SMYD3 monomethylates MAP3K2 at lysine 260, modulating the PP2A/MAP3K2 interaction and activating the downstream MAPK pathway in K-ras mutant lung and pancreatic adenocarcinoma cell lines8.